[Translation] CONQUEST: A multicenter, double-blind, randomized, placebo-controlled, phase IIb platform study to evaluate the safety and efficacy of an investigational drug in subjects with systemic sclerosis-related interstitial lung disease

本研究的主要目的是根据第 52 周治疗期结束时 FVC（mL；在 SSc-ILD 研究受试者中测量）较基线的变化来评价 IP 相比安慰剂的有效性。本研究的次要目的是评价如下内容：？根据第 52 周如下指标较基线的变化来评价 IP 相比安慰剂的有效性： o 通过高分辨率计算机断层扫描（HRCT）定量 ILD（QILD）-全肺（WL）[QILD-WL]测量的肺部受累；以及 o 通过慢性疾病治疗功能评估（FACIT）-呼吸困难评分测量的呼吸困难（严重程度和功能限制）。？第 52 周时在弥漫性皮肤型 SSc 研究受试者中通过修订版弥漫性 SSc 综合反应指数（CRISS）评分测量的总体治疗反应；以及？ IP 的安全性和耐受性。

[Translation]

The primary objective of this study was to evaluate the effectiveness of IP compared with placebo based on the change from baseline in FVC (mL; measured in SSc-ILD study subjects) at the end of the treatment period at Week 52. The secondary objectives of this study were to evaluate the following: ? To evaluate the effectiveness of IP compared with placebo based on the change from baseline at Week 52 in: o Lung involvement as measured by Quantitative ILD (QILD)-Whole Lung (WL) [QILD-WL] on high-resolution computed tomography (HRCT); and o Dyspnea (severity and functional limitation) as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnea score. ? Overall treatment response as measured by the Composite Response Index for Diffuse SSc-Revised (CRISS) score at Week 52 in diffuse cutaneous SSc study subjects; and ? The safety and tolerability of IP.

Start Date27 Jun 2025

Sponsor / Collaborator

Beijing MEDPACE Medicine Technology Co.,Ltd.

[+2]

NCT06686628

/ Active, not recruitingPhase 1

An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic Dermatitis

This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab administration at Week 25).
The number of visits will be 23 or 21 visits for participants who decide to continue amlitelimab therapy in the long-term extension study LTS17367 (RIVER-AD) study.

Start Date20 Nov 2024

Sponsor / Collaborator

Sanofi

NCT06557772

/ RecruitingPhase 2

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied.
Study details include:
The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension.
The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension.
The double-blind placebo-controlled treatment duration will be up to 28 weeks.

Start Date29 Aug 2024

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Amlitelimab

100 Translational Medicine associated with Amlitelimab

100 Patents (Medical) associated with Amlitelimab

Literatures (Medical) associated with Amlitelimab

01 Jun 2025·Journal of Scleroderma and Related Disorders

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease

Article

Author: Assassi, Shervin ; Steffgen, Juergen ; Benton, Wade W ; Maher, Toby M ; Gordon, Gregory ; Maslova, Karina ; Khanna, Dinesh ; Evnin, Luke B

Objective::

Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number of people with systemic sclerosis and further restrictions imposed by eligibility criteria. Innovative approaches are needed to accelerate development of new therapies. This article describes the rationale and trial design for CONQUEST (NCT06195072), a novel platform clinical trial sponsored by the Scleroderma Research Foundation, a not-for-profit organization.

Methods::

CONQUEST is a multicentre, double-blind, randomized, placebo-controlled, Phase 2b platform trial evaluating the efficacy, safety and pharmacodynamics of multiple investigational products to treat early active systemic sclerosis with interstitial lung disease versus placebo. The primary objective is to evaluate change from baseline to Week 52 in forced vital capacity (mL). Secondary objectives include evaluating changes from baseline to Week 52 in high-resolution computed-tomography-assessed lung involvement and dyspnoea, and overall treatment response (measured using the revised composite response index in diffuse systemic sclerosis score in participants with diffuse cutaneous systemic sclerosis).

Results::

Patients will be enrolled across more than 150 centres in over 25 countries. Recruitment started on 15 April 2024.

Conclusion::

As the first platform clinical trial in the rheumatology field, CONQUEST aims to meaningfully accelerate the development of new therapies for early active systemic sclerosis. Depending on regimen-specific results, trial data could be used to plan and design a Phase 3 trial or may be used alone or together with another registrational trial to establish substantial evidence of effectiveness and safety. The first molecules to be studied, amlitelimab and nerandomilast, both have a strong scientific rationale to modify underlying disease processes in systemic sclerosis.

ClinicalTrials.gov::

Platform Clinical Study for Conquering Scleroderma (CONQUEST); NCT06195072; https://www.clinicaltrials.gov/study/NCT06195072

01 Apr 2025·JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Article

Author: Blauvelt, Andrew ; Weidinger, Stephan ; Wei, Xiaodan ; Papp, Kim A ; Rynkiewicz, Natalie ; O'Malley, John T ; Hurbin, Fabrice ; Yen, Karl ; Adelman, Samuel ; Worm, Margitta ; Weber, Christine ; Lynde, Charles ; Wong, Wanling ; Lee, Chih-Hung ; Reich, Adam ; Foley, Peter ; Bernigaud, Charlotte ; Papp, Kim A. ; Kataoka, Yoko ; Davey, Sonya ; O’Malley, John T. ; Solente, Anne-Catherine

BACKGROUND:

Amlitelimab, a fully human nondepleting mAb targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven inflammation seen in atopic dermatitis (AD).

OBJECTIVE:

This trial evaluated the efficacy and safety of amlitelimab in adults with AD.

METHODS:

In this 2-part, phase 2b, randomized, double-blinded placebo-controlled trial (ClinicalTrials.gov identifier NCT05131477), patients received subcutaneous amlitelimab every 4 weeks at doses of 250 mg plus a 500-mg loading dose, 250 mg, 125 mg, or 62.5 mg or placebo for 24 weeks in Part 1 (1:1:1:1:1 randomization). In Part 2, clinical responders were reallocated 3:1 to stop taking amlitelimab or continue the previous dose regimen for 28 weeks. The primary end point was percentage of change in Eczema Area and Severity Index (EASI) from baseline to week 16.

RESULTS:

In all, 390 and 190 patients enrolled in Part 1 and Part 2, respectively. A significant percentage of change decrease in EASI was observed with amlitelimab doses versus with placebo (P < .001). Clinical responses at week 24 (Investigator Global Assessment 0/1 and/or a 75% reduction in EASI) were maintained at week 52 in patients continuing or stopping amlitelimab. Of the patients maintaining clinical response at week 52 after no longer receiving treatment, more than 80% had serum amlitelimab concentrations less than the 4-μg/mL threshold for several weeks before week 52. Reductions in AD-related biomarkers during Part 1 were maintained through Part 2. Amlitelimab was well tolerated over 52 weeks.

CONCLUSIONS:

Amlitelimab treatment significantly reduced clinical and biomarker responses, and was well tolerated in adults with AD through week 52. Sustained responses were observed in the majority of patients for 28 weeks after they had stopped taking amlitelimab.

01 Feb 2025·The Journal of clinical and aesthetic dermatology

Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics.

Review

Author: Al-Tariq, Kabir ; Kaiser, Michael ; Del Rosso, James ; Issa, Naiem T ; Abdin, Rama ; Kwatra, Shawn ; Jaalouk, Dana

Objective:

The authors sought to review published literature on the efficacy of biologics as monotherapy for atopic dermatitis (AD) following discontinuation.

Methods:

A comprehensive search of PubMed/MEDLINE was conducted examining drug withdrawal in AD clinical trials where participants were treated with biologics. Trials were included if they exclusively involved participants with AD that reported the maintenance or achievement of Eczema Area and Severity Index (EASI)-75 and Investigator Global Assessment (IGA) scores of 0 or 1 after withdrawal of biologic therapy. Clinical trials involving multidrug regimens, including those investigating concomitant topical therapeutics, were excluded from our analysis.

Results:

Five clinical trial programs met our inclusion criteria, each investigating a different biologic: dupilumab, tralokinumab, lebrikizumab, amlitelimab, and rocatinlimab.

Limitations:

Limitations to this review include a small number of trials that met the inclusion criteria, variations in study design that hinder direct comparisons, and the absence of long-term follow up data.

Conclusion:

The variability in eligibility criteria, treatment durations, and withdrawal periods across trials presents a major challenge in assessing biologics for AD, complicating the comparison of their sustained responses in the absence of head-to-head studies. This heterogeneity, combined with factors such as disease duration and prior use of systemic medications before trial enrollment, hampers the identification of key pathways in AD pathogenesis and impedes efforts to better understand and characterize the disease.

News (Medical) associated with Amlitelimab

31 Jul 2025

·www.globenewswire.com

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio’s DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer’s disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world’s tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: “We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.” Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press release

AcquisitionVaccinePhase 3Drug ApprovalBreakthrough Therapy

24 Jun 2025

·www.fiercebiotech.com

Investors sweet on Nektar as phase 2b eczema success doubles share price

New data sent Nektar Therapeutics’ share price up 119% to $20.90 in premarket trading. \n Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. The biotech reported a phase 2 win for rezpegaldesleukin in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Regeneron and Sanofi’s major blockbuster immunology drug Dupixent. Rezpeg, as it is also known, is an IL-pathway agonist and regulatory T-cell (Treg) proliferator. While most atopic dermatitis treatments work by blocking immune activation, rezpeg is designed to stimulate Treg cells the body makes to dampen inflammatory reactions. The idea is to rebalance the immune system to provide lasting relief from the symptoms of atopic dermatitis and other autoimmune and inflammatory diseases.Nektar tested the idea in a phase 2b trial that randomized 393 patients with moderate to severe atopic dermatitis to receive one of three doses of rezpeg or placebo. After 16 weeks, Nektar reported a 61% improvement in symptoms on the high dose and a 31% improvement on placebo, achieving its primary endpoint. The two lower doses also performed significantly better than placebo.Symptoms improved by at least 75% on the EASI score in up to 46% of patients taking rezpeg. The middle dose performed numerically better than the high dose on EASI-75 and an investigator scale. Otherwise, the data showed dose-dependent trends, with EASI-90 topping out at 25% on the high dose. The high dose performed significantly better than placebo against all the endpoints Nektar looked at in its top-line data analysis. But the high level of competition for the atopic dermatitis market means rezpeg will face tougher comparisons than placebo. EASI-75 and EASI-90 for Dupixent were 52% and 30%, respectively, in a phase 2b trial.Cytokine-, microbiome- and toleragenic-based approaches to restoring immune homeostasis are more directly comparable to rezpeg. OX40 candidates such as Sanofi’s amlitelimab are potential rivals, but Nektar believes it has a differentiated candidate. “We saw a rapid onset of response for all three endpoints and especially for EASI-75 and itch, separating from placebo quickly within a few doses of receiving rezpeg,” Nektar CEO Howard Robin said on a call with analysts to discuss the data. “This is a key differentiator from other immune-modulation approaches such as OX40 pathway inhibitors.”Jonathan Zalevsky, Ph.D., chief research and development officer at Nektar, told analysts cross-trial comparisons with OX40 studies are instructive because the trials “were completed in similar time frames, had similar global footprints and had similar statistical designs.” The biotech is now preparing for phase 3. “This study really gives us everything that we need to design the phase 3 regimen,” Zalevsky said. “I am very confident we\'re in great shape to have just one dose level and regimen for the phase three 3.”The data sent Nektar’s share price up 119% to $20.90 in premarket trading. Nektar has endured tough years since its big-ticket Bristol Myers Squibb oncology collaboration collapsed in the face of weak data. Eli Lilly was partnered on rezpeg but exited after a clinical setback. Nektar then accused Lilly of a botched analysis that understated the effect of the drug candidate.Nektar emerged with full rights to rezpeg, but, with the stock trading below cash, investor hopes were low going into the phase 2b readout. The top-line data prompted a reevaluation of Nektar’s prospects.

Phase 2Clinical ResultPhase 3Immunotherapy

02 Jun 2025

·www.biospace.com

Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio

Taylor Tieden for BioSpace Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.” Sanofi has struck a $9.5 billion deal to buy Blueprint Medicines for an approved rare disease drug and an early-stage immunology pipeline. The deal, $9.1 billion of which is upfront, will give Sanofi ownership of the systemic mastocytosis therapy Ayvakit. Blueprint posted net product revenues of $479 million in 2024 and, after achieving 61% growth in the first quarter, recently raised its guidance for this year to between $700 million and $720 million. Brian Foard, Sanofi’s head of specialty care, discussed the product’s longer-term prospects on a call with analysts Monday. The launch is “just getting started,” he said. Sanofi’s valuation of Blueprint reflects “extremely low advanced therapy penetration” so far, the executive said, and the company’s belief in the potential of Ayvakit over a long period of time. Leerink analyst Andy Berens expects that Blueprint’s revenue will hit $1.7 billion in 2030. Other observers have higher hopes, putting the consensus estimate at $2.1 billion. Leerink analyst David Risinger said in a note to investors that Sanofi “will need to deliver on its plans to find and treat more patients.” The ability of Blueprint’s pipeline to deliver blockbuster sales over the long term will be critical, too, Risinger said. There are unanswered questions about Ayvakit’s growth trajectory. Analysts asked Foard whether he expects the product to lose exclusivity in 2034 or 2040, two years in which different patents on the drug expire. Foard declined to comment beyond saying the company is “extremely comfortable with the IP.” Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.” Hudson said elenestinib’s potential is “a big deal.” Elenestinib is one of two Blueprint pipeline programs that Sanofi named as drivers of the deal. The other candidate is BLU-808, a KIT inhibitor that has applications in a range of inflammatory diseases. The deal features contingent value rights tied to development and regulatory milestones for BLU-808. Hitting the milestones will bring the total value of the deal up to $9.5 billion. Hudson said Blueprint’s “established presence among key specialist physicians” was another driver of the deal. Under Hudson, Sanofi has invested in a range of immunology candidates. Blueprint’s commercial infrastructure maps on to the capabilities Sanofi expects to need to launch its immunology drugs. “If you think about where they are today, their call points, uniquely, fit us perfectly,” Foard said. “Think about our pipeline that is being built right now with amlitelimab, with lunsekimig, with TL1A. The call points for those assets are going to be dermatologists, allergists, GIs, which is exactly where Blueprint is today. So, it is going to be a natural build around these individuals.” Sanofi, which is selling a controlling stake in its consumer-healthcare arm, has struck three takeovers this year. The Blueprint deal joins agreements to buy Dren Bio and Vigil Neuroscience for $600 million and $470 million upfront, respectively. The buyouts have added to a pipeline that Hudson said has endured “a bumpy year in terms of some of the readouts.” The Blueprint takeover is at the upper end of the valuation range that Hudson has told investors Sanofi will look at. Yet, the buyout, which Sanofi will finance through cash and new debt, has not sated the company’s appetite. Sanofi CFO François-Xavier Roger told analysts the company retains “significant capacity for further business development, particularly in early-stage medicines and vaccines.”

AcquisitionImmunotherapy

100 Deals associated with Amlitelimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate Atopic Dermatitis	Phase 3	United States	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	China	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Argentina	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Australia	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Brazil	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Canada	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Chile	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	France	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Germany	Sanofi	08 Nov 2023
Moderate Atopic Dermatitis	Phase 3	Greece	Sanofi	08 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05421598 (TIDE-Asthma, Company_Website) Manual	Phase 2	Asthma Adjuvant	437	Amlitelimab	tviakhpznz(tgevjhzxnr) = the primary endpoint of annualized exacerbation rate at week 48 was not met at the highest dose level. zpqopoupzx (mpgqaragly ) Not Met	Negative	15 Apr 2025
				Placebo
NCT05131477 (STREAM-AD, Pubmed) Manual	Phase 2	Dermatitis, Atopic	580	Amlitelimab (Part 1)	cwxpcprbnx(askrkkariq): P-Value = < 0.001	Positive	08 Nov 2024
				Amlitelimab (Part 2)
NCT05131477 (STREAM-AD, GlobeNewswire) Manual	Phase 2	Dermatitis, Atopic	390	amlitelimab (patients with continued treatment)	ufxcuyoukf(vdinpkekbf) = qhpllbywnn dbbgptaajs (trqgdchkbr ) View more	Positive	11 Mar 2024
				amlitelimab (patients withdrawn from treatment)	ufxcuyoukf(vdinpkekbf) = xqrmyznsft dbbgptaajs (trqgdchkbr ) View more
NCT05131477 (STREAM-AD, NEWS) Manual	Phase 2	Dermatitis, Atopic	390	amlitelimab	bmmojtqwzg(gbchlovaro) = outloaxyny oujcjbrmpw (peupwnuxfn ) View more	Positive	15 Oct 2023
				placebo	bmmojtqwzg(gbchlovaro) = nqtgtkwybp oujcjbrmpw (peupwnuxfn ) View more
NCT03754309 (AAD2023)	Phase 2	Dermatitis, Atopic	89	Amlitelimab low-dose	tadraqmpij(ecydebuthz) = 1 SAE (infected dermal cyst) was reported as possibly related; it resolved and the patient completed the study otoetetunt (xanmkawqiw ) View more	-	17 Mar 2023
				Amlitelimab high-dose
NCT03754309 (Phase 2a, EADV2022)	Phase 2	Dermatitis, Atopic IL-22	89	Amlitelimab low dose (200 mg loading/100 mg maintenance every 4 weeks [Q4W])	avvybggegx(lpscmhzbay) = qwlcxnenjt qwdlxmcqji (fejqlobfgb )	Positive	07 Sep 2022
				Amlitelimab high dose (500 mg/250 mg Q4W)	avvybggegx(lpscmhzbay) = splslflcpp qwdlxmcqji (fejqlobfgb )
NCT03161288 (Pubmed \| Clin Pharmacol Ther)	Phase 1	-	64	KY1005	ikrmvyazow(kupccvvhty) = No serious adverse events occurred and all adverse events were temporary and of mild or moderate severity. xcyjfajpdm (bzzjymbkim ) View more	-	29 Jan 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis